Skip to content
The Policy VaultThe Policy Vault

Releuko — Medica

Cytokine Release Syndrome associated with Chimeric Antigen Receptor (CAR) T-cell therapy in patients with neutropenia

Initial criteria

  • Prescribed for a patient who has neutropenia

Approval duration

1 month